Results 11 to 20 of about 1,414 (186)
Conbercept for patients with age-related macular degeneration: a systematic review [PDF]
BMC Ophthalmology, 2018 Background Conbercept is a novel vascular endothelial growth factor (VEGF) inhibitor for the treatment of wet age-related macular degeneration (AMD). This systematic review aims to assess the efficacy and safety of conbercept in the treatment of wet AMD.
Jiaxing Zhang +7 more
doaj +4 more sources
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review [PDF]
Journal of Ophthalmology, 2020 Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (
Yimin Wang +4 more
doaj +5 more sources
BMC OphthalmologyBackground To determine the efficacy and safety of intravitreally injected conbercept, a vascular endothelial growth factor receptor fusion protein, for the treatment of idiopathic choroidal neovascularization (ICNV).
Gaixia Zhai +4 more
doaj +4 more sources
Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration [PDF]
International Journal of Ophthalmology, 2023 AIM: To evaluate the clinical efficacy and systemic safety profile of conbercept in clinical practice on vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PLGF) levels after intravitreal injections for the neovascular age ...
Xiao-Dong Chen +5 more
doaj +2 more sources
Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series [PDF]
BMC Ophthalmology, 2019 Background There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpose of this study is to describe the
Zhongjing Lin +4 more
doaj +4 more sources
Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. [PDF]
PLoS ONE, 2013 VEGF family factors are known to be the principal stimulators of abnormal angiogenesis, which play a fundamental role in tumor and various ocular diseases. Inhibition of VEGF is widely applied in antiangiogenic therapy.
Qin Wang +6 more
doaj +2 more sources
Journal of Ophthalmology, 2021 Objective. This meta-analysis aimed to compare the effect and safety of conbercept with panretinal photocoagulation (PRP) vs. PRP in the treatment of diabetic retinopathy (DR). Methods. Relevant studies were identified through systemic searches of PubMed,
Chao Huang, Haiqing Ji, Xuguang Han
doaj +2 more sources
Scientific Reports, 2017 The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the alteration of the structure, the newest drug is capable of combining more molecular targets and present higher affinity to the ...
Jiaming Wang +6 more
doaj +2 more sources
The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy [PDF]
Journal of Ophthalmology, 2019 Purpose. To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC). Methods. A retrospective clinical study. Thirty-one patients (35 eyes) with chronic CSC were given intravitreal injections of conbercept and followed up for at least 6 months.
Jianbo Mao +7 more
openaire +4 more sources
The efficacy and safety of aflibercept and conbercept in diabetic macular edema
Drug Design, Development and Therapy, 2018 Diabetic macular edema (DME) has shown an increasing prevalence during the past years and is the leading cause of diabetic retinopathy blindness. Traditional treatment modalities include laser and corticosteroid therapy, which, however, either act through unclear mechanisms or cause cataracts and elevated intraocular pressure.
Siwei Cai +3 more
core +7 more sources